1-3 of 3
Robert M Sharkey, Ph.D.
Close
Sort by
Journal Articles

A New Antibody-Drug Conjugate Composed of an Anti-HLA-DR IgG4 Antibody, IMMU-114, and SN-38, Is Active in Experimental Acute Myelocytic Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and Multiple Myeloma (MM)

David M Goldenberg, ScD, MD, Robert M Sharkey, Ph.D., Serengulam V Govindan, PhD, Maria Zalath, BA, Ali Mostafa, BS, Thomas M Cardillo, Ph.D.
Journal: Blood
Blood (2016) 128 (22): 3958.
https://doi.org/10.1182/blood.V128.22.3958.3958
Published: 2016
Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.
Journal: Blood
Blood (2010) 116 (21): 3941.
https://doi.org/10.1182/blood.V116.21.3941.3941
Published: 2010
Journal Articles

Radioimmunotherapy of Non-Hodgkin Lymphoma is Improved without Increasing Toxicity by Combination with Antibody immunotherapy.

Robert M Sharkey, Ph.D., M. Jules Mattes, Ph.D., Habibe Karacay, Ph.D., Chien-Hsing Chang, PhD, Edmund A Rossi, PhD, William J McBride, Ph.D., David M. Goldenberg, ScD, MD
Journal: Blood
Blood (2008) 112 (11): 1588.
https://doi.org/10.1182/blood.V112.11.1588.1588
Published: 2008